미국의 동물용 재생의료 시장 규모, 점유율, 동향 분석 : 제품별, 동물 종류별, 용도별, 최종 용도별, 부문별 예측(2025-2033년)

Market Size & Trends:

The U.S. veterinary regenerative medicine market size was estimated at USD 108.07 million in 2024 and is projected to reach at USD 281.68 million by 2033, growing at a CAGR of 11.5% from 2025 to 2033. The market is primarily driven by the growing prevalence of chronic conditions such as arthritis, osteoarthritis, and tendon injuries in companion animals, which is increasing the demand for advanced therapeutic solutions. Rising pet ownership and the willingness of owners to spend more on specialized veterinary care have further fueled the adoption of regenerative approaches such as stem cell therapy and tissue engineering. In addition, continuous technological advancements and rising investments by veterinary biotechnology companies are accelerating innovation and expanding the availability of regenerative medicine products in the country.

Clinical studies play a pivotal role in driving the growth of the U.S. veterinary regenerative medicine market by providing scientific validation and regulatory credibility to advanced therapies. For instance, according to the FDA, clinical studies on autologous adipose- or bone marrow-derived mesenchymal stem cells for canine musculoskeletal and nervous system diseases are being conducted in the U.S., specifically in New York. Such studies not only demonstrate the safety and efficacy of regenerative therapies in treating conditions such as arthritis and tendon injuries but also build confidence among veterinarians and pet owners, thereby accelerating adoption. Moreover, positive clinical outcomes encourage regulatory support, foster industry collaborations, and attract investments from biotechnology companies, further strengthening innovation pipelines. By translating cutting-edge research into practical veterinary applications, these clinical trials significantly contribute to expanding the acceptance, commercialization, and long-term growth of the veterinary regenerative medicine market in the country.

Moreover, the presence of veterinary research colleges and institutes offering regenerative medicine services significantly drives the growth of the U.S. veterinary regenerative medicine market by serving as centers of innovation, training, and service delivery. For example, the University of Tennessee Institute of Agriculture provides advanced services such as isolation and expansion of bone marrow-derived mesenchymal stem cells in dogs, and preparation of these stem cells for therapeutic injections. Such institutions not only support clinical applications but also promote research and development, enabling faster translation of regenerative techniques into veterinary practice. By offering specialized services and expertise, they increase accessibility for veterinarians and pet owners, build trust in advanced treatments, and enhance awareness of regenerative therapies. Furthermore, these centers act as hubs for collaborations with biotechnology firms and regulatory bodies, ultimately expanding the commercialization and acceptance of regenerative medicine across the U.S. veterinary healthcare landscape.

U.S. Veterinary Regenerative Medicine Market Report Segmentation

This report forecasts revenue growth provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary regenerative medicine market report based on product, animal type, application, end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Stem Cells
  • Others
• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Small Animals
  • Large Animals
• Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Orthopedics
  • Trauma/Wound Care
  • Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Clinics & Hospitals
  • Veterinary Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
  • 1.3.5. Details of Primary Research
  • 1.3.6. Data analysis model
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Regenerative Medicine Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of orthopedic disorders in pets
    • 3.2.1.2. Rising pet expenditure and pet humanization
    • 3.2.1.3. Strategic initiatives by key players
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of treatment.
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Veterinary Regenerative Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Legal landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Technological landscape
    • 3.3.2.6. Environmental landscape
• 3.4. Pricing Analysis
• 3.5. Regulatory Framework
• 3.6. Estimated Animal Population by key Species, key countries, 2021 - 2024

Chapter 4. U.S. Veterinary Regenerative Medicine Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Veterinary Regenerative Medicine Market: Product Movement Analysis
• 4.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Stem Cells
  • 4.4.1. Stem Cells Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.5. Others
  • 4.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 5. U.S. Veterinary Regenerative Medicine Market: Animal Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Veterinary Regenerative Medicine Market: Animal Type Movement Analysis
• 5.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Animal Type, 2021 to 2033 (USD Million)
• 5.4. Small Animals
  • 5.4.1. Small Animals Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.5. Large Animals
  • 5.5.1. Large Animals Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 6. U.S. Veterinary Regenerative Medicine Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Veterinary Regenerative Medicine Market: Application Movement Analysis
• 6.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Orthopedics
  • 6.4.1. Orthopedics Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
  • 6.4.2. Trauma/Wound Care
  • 6.4.3. Trauma/Wound Care Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 7. U.S. Veterinary Regenerative Medicine Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Veterinary Regenerative Medicine Market: By End Use Movement Analysis
• 7.3. U.S. Veterinary Regenerative Medicine Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Clinics & Hospitals
    • 7.3.1.1. Veterinary Clinics & Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)
  • 7.3.2. Veterinary Research Institute
    • 7.3.2.1. Veterinary Research Institute Market Revenue Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Position Analysis/ Heat Map Analysis
• 8.3. Company Profiles
  • 8.3.1. Boehringer Ingelheim International GmbH
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product/Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Zoetis
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product/Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Dechra Pharmaceuticals PLC
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product/Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Equine Amnio Solutions
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product/Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. VetStem, Inc
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product/Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Hilltop Bio
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product/Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Equi-Stem LLC
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product/Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Ardent Equine
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product/Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Pronoia Biotech
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product/Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. AniCell BioTech
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product/Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
• 8.4. Strategy Mapping
  • 8.4.1. Mergers & Acquisitions
  • 8.4.2. Partnerships & Collaborations
  • 8.4.3. Product/Service launch
  • 8.4.4. Others
• 8.5. List of other key players